NSG 5240 Advanced Pharmacology Final Exam Prep
Document | 2026/2027 Edition | 250 Verified Questions
NSG 5240 Advanced Pharmacology Final Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED
A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document contains 250 evidence-based, verified questions and
answers for the NSG 5240 Advanced Pharmacology final exam. Each question is aligned with the
latest 2026/2027 curriculum guidelines and includes detailed rationales to reinforce key
pharmacological concepts. Designed to support mastery of advanced pharmacotherapeutics, this
resource ensures students are thoroughly prepared for exam success.
Key Features:
Pharmacokinetics and Pharmacodynamics
Autonomic and Cardiovascular Pharmacology
Central Nervous System Agents
Endocrine and Metabolic Pharmacotherapy
Antimicrobial and Anti-inflammatory Agents
Oncology and Immunomodulators
Updates for 2026:
- Incorporated 2026 FDA drug approvals and safety alerts
- Revised rationales to reflect current clinical practice guidelines
- Added new questions on biologic and targeted therapies
- Updated drug interaction and adverse effect profiles
- Enhanced coverage of geriatric and pediatric dosing considerations
Abstract:
This document presents a rigorous compilation of 250 multiple-choice questions for the NSG 5240 Advanced
Pharmacology final exam, each accompanied by evidence-based verified answers and detailed rationales. The
content spans core areas including pharmacokinetics, autonomic pharmacology, cardiovascular agents, central
nervous system drugs, endocrine therapies, antimicrobials, anti-inflammatory agents, and oncology
pharmacotherapy. Questions are designed to test both foundational knowledge and clinical application, with
distractors reflecting common misconceptions. Updated for the 2026/2027 academic year, this resource integrates
the latest FDA approvals, black box warnings, and guideline-directed therapies. Rationales explain correct
answers and clarify why incorrect options are wrong, promoting deep learning. This exam prep tool is ideal for
nurse practitioner students seeking to excel in advanced pharmacology and achieve a graded A+ performance.
Keywords:
Advanced Pharmacology, NSG 5240, Final Exam, 250 Questions, Evidence-Based Answers, Nurse Practitioner,
Pharmacotherapeutics, 2026-2027
Answer Format:
Each question is followed by the correct answer and a detailed rationale explaining the underlying pharmacology,
mechanism of action, clinical application, and why each distractor is incorrect. Rationales are concise yet
comprehensive, referencing current guidelines and drug labeling.
Compliance Checklist:
All questions align with 2026/2027 NSG 5240 curriculum objectives
Answers verified against latest FDA labeling and clinical guidelines
Rationales include evidence-based citations where applicable
Page 1
, Distractors reflect common student errors and misconceptions
Content covers all major drug classes and therapeutic areas
Suitable for self-assessment and final exam review
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, Distribution, Metabolism, 12%
Pharmacodynamics Excretion, Receptor theory, Dose-response
Autonomic and Cardiovascular 31-70 Adrenergic agonists/antagonists, Cholinergic 16%
Pharmacology agents, Antihypertensives, Antiarrhythmics,
Anticoagulants
Central Nervous System Agents 71-110 Anxiolytics, Antidepressants, 16%
Antipsychotics, Antiepileptics, Opioid
analgesics
Endocrine and Metabolic 111-150 Diabetes agents, Thyroid drugs, 16%
Pharmacotherapy Corticosteroids, Osteoporosis therapies,
Lipid-lowering agents
Antimicrobial and 151-200 Antibiotics, Antivirals, Antifungals, 20%
Anti-inflammatory Agents NSAIDs, DMARDs, Immunosuppressants
Oncology and 201-250 Chemotherapy agents, Targeted therapy, 20%
Immunomodulators Immunotherapy, Monoclonal antibodies,
Vaccines
Page 2
,Q1. A patient with a history of recurrent atrial fibrillation is prescribed digoxin 0.125 mg daily.
Which of the following concurrent medications most significantly increases the risk of digoxin
toxicity due to a pharmacokinetic interaction at the P-glycoprotein transporter?
A. Amiodarone
B. Metoprolol
C. Warfarin
D. Lisinopril
Correct Answer: A. Amiodarone
Rationale: Amiodarone inhibits P-glycoprotein (P-gp) in the intestine and kidney, reducing digoxin
clearance and increasing serum digoxin levels. Metoprolol may have additive bradycardic effects but
does not affect digoxin pharmacokinetics. Warfarin and lisinopril have no significant P-gp interaction.
Why Wrong:
B - Metoprolol does not inhibit P-glycoprotein; its interaction with digoxin is primarily
pharmacodynamic (additive bradycardia).
C - Warfarin is highly protein-bound and metabolized by CYP450, but does not affect P-gp mediated
digoxin transport.
D - Lisinopril is an ACE inhibitor with no known effect on digoxin clearance via P-glycoprotein.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 56; Katzung, B.G. (2025).
Basic & Clinical Pharmacology, 16th Ed., Ch. 35.
Q2. A 45-year-old patient with type 2 diabetes and chronic kidney disease (eGFR 35 mL/min/1.73
m²) is being started on an SGLT2 inhibitor. Which of the following agents is most appropriate given
the renal function?
A. Canagliflozin
B. Dapagliflozin
C. Empagliflozin
D. Ertugliflozin
Correct Answer: B. Dapagliflozin
Rationale: Dapagliflozin is approved for use down to eGFR "e25 mL/min/1.73 m² for glycemic control
and heart failure. Canagliflozin and empagliflozin have restrictions at eGFR <30-45 mL/min.
Ertugliflozin is not recommended when eGFR <30 mL/min.
Why Wrong:
A - Canagliflozin is not recommended for glycemic control when eGFR is <30 mL/min, though it
may be used for diabetic nephropathy at higher eGFR.
C - Empagliflozin is not recommended for glycemic control when eGFR is <30 mL/min; its
cardiovascular indications require eGFR 30 mL/min.
D - Ertugliflozin is not recommended when eGFR is <30 mL/min.
Reference: 2026 ADA Standards of Care; FDA prescribing information for SGLT2 inhibitors.
Page 3
, Q3. A patient with severe hypertension (BP 185/115 mm Hg) and no contraindications is started on
intravenous nitroprusside. Which of the following adverse effects is most likely to occur with
prolonged infusion (>48 hours) and warrants monitoring of serum thiocyanate levels?
A. Methemoglobinemia
B. Cyanide toxicity
C. Thiocyanate toxicity
D. Lactic acidosis
Correct Answer: C. Thiocyanate toxicity
Rationale: Nitroprusside is metabolized to cyanide, which is then converted to thiocyanate in the liver.
Thiocyanate accumulates with prolonged infusion, especially in renal impairment, causing toxicity
(confusion, psychosis, hyperreflexia). Cyanide toxicity is rare with standard doses and adequate hepatic
function.
Why Wrong:
A - Methemoglobinemia is a rare adverse effect of nitrates but not typically associated with
nitroprusside.
B - Cyanide toxicity can occur but is less common than thiocyanate toxicity with prolonged infusion;
thiocyanate is the major metabolite measured.
D - Lactic acidosis may occur with cyanide toxicity but is not the direct toxic metabolite monitored.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 43; Katzung, B.G. (2025).
Basic & Clinical Pharmacology, 16th Ed., Ch. 19.
Q4. Which of the following statements best explains why warfarin requires several days to achieve
full therapeutic effect, even after a loading dose?
A. Warfarin has a long elimination half-life of approximately 40 hours.
B. Warfarin inhibits the synthesis of vitamin K-dependent clotting factors, but existing factors must be
cleared from circulation.
C. Warfarin requires hepatic metabolism to its active metabolite, which accumulates slowly.
D. Warfarin directly inhibits thrombin, requiring time for receptor desensitization.
Correct Answer: B. Warfarin inhibits the synthesis of vitamin K-dependent clotting factors, but
existing factors must be cleared from circulation.
Rationale: Warfarin acts by inhibiting the synthesis of vitamin K-dependent factors (II, VII, IX, X). The
onset of anticoagulation is delayed until pre-existing clotting factors are naturally degraded. Factor VII
has a short half-life (6-8 hours), but full effect requires depletion of factor II (half-life ~60 hours).
Why Wrong:
A - The half-life of warfarin is about 40 hours, but the delay in therapeutic effect is primarily due to
the lifespan of existing clotting factors, not the drug's half-life.
C - Warfarin is a prodrug metabolized to inactive metabolites; it does not require activation to an
active form.
D - Warfarin does not directly inhibit thrombin; it reduces synthesis of factors that eventually lead to
thrombin generation.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 64; Brunton, L.L. (2025).
Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th Ed., Ch. 30.
Page 4
Document | 2026/2027 Edition | 250 Verified Questions
NSG 5240 Advanced Pharmacology Final Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED
A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document contains 250 evidence-based, verified questions and
answers for the NSG 5240 Advanced Pharmacology final exam. Each question is aligned with the
latest 2026/2027 curriculum guidelines and includes detailed rationales to reinforce key
pharmacological concepts. Designed to support mastery of advanced pharmacotherapeutics, this
resource ensures students are thoroughly prepared for exam success.
Key Features:
Pharmacokinetics and Pharmacodynamics
Autonomic and Cardiovascular Pharmacology
Central Nervous System Agents
Endocrine and Metabolic Pharmacotherapy
Antimicrobial and Anti-inflammatory Agents
Oncology and Immunomodulators
Updates for 2026:
- Incorporated 2026 FDA drug approvals and safety alerts
- Revised rationales to reflect current clinical practice guidelines
- Added new questions on biologic and targeted therapies
- Updated drug interaction and adverse effect profiles
- Enhanced coverage of geriatric and pediatric dosing considerations
Abstract:
This document presents a rigorous compilation of 250 multiple-choice questions for the NSG 5240 Advanced
Pharmacology final exam, each accompanied by evidence-based verified answers and detailed rationales. The
content spans core areas including pharmacokinetics, autonomic pharmacology, cardiovascular agents, central
nervous system drugs, endocrine therapies, antimicrobials, anti-inflammatory agents, and oncology
pharmacotherapy. Questions are designed to test both foundational knowledge and clinical application, with
distractors reflecting common misconceptions. Updated for the 2026/2027 academic year, this resource integrates
the latest FDA approvals, black box warnings, and guideline-directed therapies. Rationales explain correct
answers and clarify why incorrect options are wrong, promoting deep learning. This exam prep tool is ideal for
nurse practitioner students seeking to excel in advanced pharmacology and achieve a graded A+ performance.
Keywords:
Advanced Pharmacology, NSG 5240, Final Exam, 250 Questions, Evidence-Based Answers, Nurse Practitioner,
Pharmacotherapeutics, 2026-2027
Answer Format:
Each question is followed by the correct answer and a detailed rationale explaining the underlying pharmacology,
mechanism of action, clinical application, and why each distractor is incorrect. Rationales are concise yet
comprehensive, referencing current guidelines and drug labeling.
Compliance Checklist:
All questions align with 2026/2027 NSG 5240 curriculum objectives
Answers verified against latest FDA labeling and clinical guidelines
Rationales include evidence-based citations where applicable
Page 1
, Distractors reflect common student errors and misconceptions
Content covers all major drug classes and therapeutic areas
Suitable for self-assessment and final exam review
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, Distribution, Metabolism, 12%
Pharmacodynamics Excretion, Receptor theory, Dose-response
Autonomic and Cardiovascular 31-70 Adrenergic agonists/antagonists, Cholinergic 16%
Pharmacology agents, Antihypertensives, Antiarrhythmics,
Anticoagulants
Central Nervous System Agents 71-110 Anxiolytics, Antidepressants, 16%
Antipsychotics, Antiepileptics, Opioid
analgesics
Endocrine and Metabolic 111-150 Diabetes agents, Thyroid drugs, 16%
Pharmacotherapy Corticosteroids, Osteoporosis therapies,
Lipid-lowering agents
Antimicrobial and 151-200 Antibiotics, Antivirals, Antifungals, 20%
Anti-inflammatory Agents NSAIDs, DMARDs, Immunosuppressants
Oncology and 201-250 Chemotherapy agents, Targeted therapy, 20%
Immunomodulators Immunotherapy, Monoclonal antibodies,
Vaccines
Page 2
,Q1. A patient with a history of recurrent atrial fibrillation is prescribed digoxin 0.125 mg daily.
Which of the following concurrent medications most significantly increases the risk of digoxin
toxicity due to a pharmacokinetic interaction at the P-glycoprotein transporter?
A. Amiodarone
B. Metoprolol
C. Warfarin
D. Lisinopril
Correct Answer: A. Amiodarone
Rationale: Amiodarone inhibits P-glycoprotein (P-gp) in the intestine and kidney, reducing digoxin
clearance and increasing serum digoxin levels. Metoprolol may have additive bradycardic effects but
does not affect digoxin pharmacokinetics. Warfarin and lisinopril have no significant P-gp interaction.
Why Wrong:
B - Metoprolol does not inhibit P-glycoprotein; its interaction with digoxin is primarily
pharmacodynamic (additive bradycardia).
C - Warfarin is highly protein-bound and metabolized by CYP450, but does not affect P-gp mediated
digoxin transport.
D - Lisinopril is an ACE inhibitor with no known effect on digoxin clearance via P-glycoprotein.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 56; Katzung, B.G. (2025).
Basic & Clinical Pharmacology, 16th Ed., Ch. 35.
Q2. A 45-year-old patient with type 2 diabetes and chronic kidney disease (eGFR 35 mL/min/1.73
m²) is being started on an SGLT2 inhibitor. Which of the following agents is most appropriate given
the renal function?
A. Canagliflozin
B. Dapagliflozin
C. Empagliflozin
D. Ertugliflozin
Correct Answer: B. Dapagliflozin
Rationale: Dapagliflozin is approved for use down to eGFR "e25 mL/min/1.73 m² for glycemic control
and heart failure. Canagliflozin and empagliflozin have restrictions at eGFR <30-45 mL/min.
Ertugliflozin is not recommended when eGFR <30 mL/min.
Why Wrong:
A - Canagliflozin is not recommended for glycemic control when eGFR is <30 mL/min, though it
may be used for diabetic nephropathy at higher eGFR.
C - Empagliflozin is not recommended for glycemic control when eGFR is <30 mL/min; its
cardiovascular indications require eGFR 30 mL/min.
D - Ertugliflozin is not recommended when eGFR is <30 mL/min.
Reference: 2026 ADA Standards of Care; FDA prescribing information for SGLT2 inhibitors.
Page 3
, Q3. A patient with severe hypertension (BP 185/115 mm Hg) and no contraindications is started on
intravenous nitroprusside. Which of the following adverse effects is most likely to occur with
prolonged infusion (>48 hours) and warrants monitoring of serum thiocyanate levels?
A. Methemoglobinemia
B. Cyanide toxicity
C. Thiocyanate toxicity
D. Lactic acidosis
Correct Answer: C. Thiocyanate toxicity
Rationale: Nitroprusside is metabolized to cyanide, which is then converted to thiocyanate in the liver.
Thiocyanate accumulates with prolonged infusion, especially in renal impairment, causing toxicity
(confusion, psychosis, hyperreflexia). Cyanide toxicity is rare with standard doses and adequate hepatic
function.
Why Wrong:
A - Methemoglobinemia is a rare adverse effect of nitrates but not typically associated with
nitroprusside.
B - Cyanide toxicity can occur but is less common than thiocyanate toxicity with prolonged infusion;
thiocyanate is the major metabolite measured.
D - Lactic acidosis may occur with cyanide toxicity but is not the direct toxic metabolite monitored.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 43; Katzung, B.G. (2025).
Basic & Clinical Pharmacology, 16th Ed., Ch. 19.
Q4. Which of the following statements best explains why warfarin requires several days to achieve
full therapeutic effect, even after a loading dose?
A. Warfarin has a long elimination half-life of approximately 40 hours.
B. Warfarin inhibits the synthesis of vitamin K-dependent clotting factors, but existing factors must be
cleared from circulation.
C. Warfarin requires hepatic metabolism to its active metabolite, which accumulates slowly.
D. Warfarin directly inhibits thrombin, requiring time for receptor desensitization.
Correct Answer: B. Warfarin inhibits the synthesis of vitamin K-dependent clotting factors, but
existing factors must be cleared from circulation.
Rationale: Warfarin acts by inhibiting the synthesis of vitamin K-dependent factors (II, VII, IX, X). The
onset of anticoagulation is delayed until pre-existing clotting factors are naturally degraded. Factor VII
has a short half-life (6-8 hours), but full effect requires depletion of factor II (half-life ~60 hours).
Why Wrong:
A - The half-life of warfarin is about 40 hours, but the delay in therapeutic effect is primarily due to
the lifespan of existing clotting factors, not the drug's half-life.
C - Warfarin is a prodrug metabolized to inactive metabolites; it does not require activation to an
active form.
D - Warfarin does not directly inhibit thrombin; it reduces synthesis of factors that eventually lead to
thrombin generation.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 64; Brunton, L.L. (2025).
Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th Ed., Ch. 30.
Page 4
